What the FDA labels say about taking them together
Cedazuridine/decitabine and venetoclax
Cedazuridine/decitabine's FDA label of May 25, 2026 names venetoclax in its warnings and precautions section; the venetoclax label PlainMeds reads does not name cedazuridine/decitabine.
Check it at the source: the cedazuridine/decitabine FDA label on DailyMed (effective May 25, 2026, Taiho Pharmaceutical Co., Ltd.); the venetoclax FDA label on DailyMed (effective May 20, 2026, AbbVie Inc.).
What does the cedazuridine/decitabine label say about venetoclax?
Cedazuridine/decitabine label, warnings and precautionsINQOVI in Combination with Venetoclax for AML In patients with AML, INQOVI can cause severe myelosuppression, including fatal adverse reactions, when given in combination with venetoclax.
Source: FDA drug label (INQOVI), Taiho Pharmaceutical Co., Ltd., effective May 25, 2026 (SPL set 91a0f80b-f865-4d06-a40d-4d148d99ee71), via openFDA; the full label on DailyMed
What does the venetoclax label say about cedazuridine/decitabine?
Venetoclax's label (effective May 20, 2026) does not name cedazuridine/decitabine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Venclexta), AbbVie Inc., effective May 20, 2026 (SPL set b118a40d-6b56-cee3-10f6-ded821a97018), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cedazuridine/decitabine | Venetoclax | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once